Inhibitors of Protein Kinases and Protein Phosphates

The Editor (L.A. Pinna) is full Professor of Medical Chemistry at the University of Padova since 1975. He has been involved for over 30 years in the study of various aspects of protein phosphorylation, with special reference to the analysis of consensus sequences of protein kinases and the development of peptide substrates for the specific monitoring of individual members of this family of enzymes. In this field he has published more than 290 original pepers and a number of review articles in international journals. Over the last years he has provided major contributions to the molecular and structural enzymology of protein kinases implicated in cell fate decision and in the development of inhibitors of one of these enzymes.The co-Editor (P.T.W. Cohen) is an authority in the field of protein phosphatases.

• Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems.- General Aspects of PKs Inhibition.- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases.- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3.- Pharmacological Potential of p38 MAPK Inhibitors.- Inhibitors of PKA and Related Protein Kinases.- Inhibitors of Protein Kinase CK2: Structural Aspects.- Aminoglycoside Kinases and Antibiotic Resistance.- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases.- Protein Tyrosine Phosphatases as Therapeutic Targets.- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors.- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target.- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity.- Inhibitors in Clinical Use or Advanced Clinical Trials.- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus.- Targeted Therapy with Imatinib: An Exception or a Rule?.- Clinical Aspects of Imatinib Therapy.- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy.- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.